Peptide-based PET quantifies target engagement of PD-L1 therapeutics

Dhiraj Kumar, Ala Lisok, Elyes Dahmane, Matthew McCoy, Sagar Shelake, Samit Chatterjee, Viola Allaj, Polina Sysa-Shah, Bryan Wharram, Wojciech Lesniak, Ellen Tully, Edward Gabrielson, Elizabeth Jaffee, John T. Poirier, Charles M. Rudin, Jogarao V.S. Gobburu, Martin Gilbert Pomper, Sridhar Nimmagadda

Research output: Contribution to journalArticle

Abstract

Immune checkpoint therapies have shown tremendous promise in cancer therapy. However, tools to assess their target engagement, and hence the ability to predict their efficacy, have been lacking. Here, we show that target engagement and tumor-residence kinetics of antibody therapeutics targeting programmed death ligand-1 (PD-L1) can be quantified noninvasively. In computational docking studies, we observed that PD-L1–targeted monoclonal antibodies (atezolizumab, avelumab, and durvalumab) and a high-affinity PD-L1–binding peptide, WL12, have common interaction sites on PD-L1. Using the peptide radiotracer [64Cu]WL12 in vivo, we employed positron emission tomography (PET) imaging and biodistribution studies in multiple xenograft models and demonstrated that variable PD-L1 expression and its saturation by atezolizumab, avelumab, and durvalumab can be quantified independently of biophysical properties and pharmacokinetics of antibodies. Next, we used [64Cu]WL12 to evaluate the impact of time and dose on the unoccupied fraction of tumor PD-L1 during treatment. These quantitative measures enabled, by mathematical modeling, prediction of antibody doses needed to achieve therapeutically effective occupancy (defined as >90%). Thus, we show that peptide-based PET is a promising tool for optimizing dose and therapeutic regimens employing PD-L1 checkpoint antibodies, and can be used for improving therapeutic efficacy.

Original languageEnglish (US)
Pages (from-to)616-630
Number of pages15
JournalJournal of Clinical Investigation
Volume129
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Positron-Emission Tomography
Ligands
Peptides
Antibodies
Therapeutics
Neoplasms
Heterografts
Pharmacokinetics
Monoclonal Antibodies
MPDL3280A
avelumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kumar, D., Lisok, A., Dahmane, E., McCoy, M., Shelake, S., Chatterjee, S., ... Nimmagadda, S. (2019). Peptide-based PET quantifies target engagement of PD-L1 therapeutics. Journal of Clinical Investigation, 129(2), 616-630. https://doi.org/10.1172/JCI122216

Peptide-based PET quantifies target engagement of PD-L1 therapeutics. / Kumar, Dhiraj; Lisok, Ala; Dahmane, Elyes; McCoy, Matthew; Shelake, Sagar; Chatterjee, Samit; Allaj, Viola; Sysa-Shah, Polina; Wharram, Bryan; Lesniak, Wojciech; Tully, Ellen; Gabrielson, Edward; Jaffee, Elizabeth; Poirier, John T.; Rudin, Charles M.; Gobburu, Jogarao V.S.; Pomper, Martin Gilbert; Nimmagadda, Sridhar.

In: Journal of Clinical Investigation, Vol. 129, No. 2, 01.02.2019, p. 616-630.

Research output: Contribution to journalArticle

Kumar, D, Lisok, A, Dahmane, E, McCoy, M, Shelake, S, Chatterjee, S, Allaj, V, Sysa-Shah, P, Wharram, B, Lesniak, W, Tully, E, Gabrielson, E, Jaffee, E, Poirier, JT, Rudin, CM, Gobburu, JVS, Pomper, MG & Nimmagadda, S 2019, 'Peptide-based PET quantifies target engagement of PD-L1 therapeutics', Journal of Clinical Investigation, vol. 129, no. 2, pp. 616-630. https://doi.org/10.1172/JCI122216
Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S et al. Peptide-based PET quantifies target engagement of PD-L1 therapeutics. Journal of Clinical Investigation. 2019 Feb 1;129(2):616-630. https://doi.org/10.1172/JCI122216
Kumar, Dhiraj ; Lisok, Ala ; Dahmane, Elyes ; McCoy, Matthew ; Shelake, Sagar ; Chatterjee, Samit ; Allaj, Viola ; Sysa-Shah, Polina ; Wharram, Bryan ; Lesniak, Wojciech ; Tully, Ellen ; Gabrielson, Edward ; Jaffee, Elizabeth ; Poirier, John T. ; Rudin, Charles M. ; Gobburu, Jogarao V.S. ; Pomper, Martin Gilbert ; Nimmagadda, Sridhar. / Peptide-based PET quantifies target engagement of PD-L1 therapeutics. In: Journal of Clinical Investigation. 2019 ; Vol. 129, No. 2. pp. 616-630.
@article{64963098813d46998584c66b2a12505f,
title = "Peptide-based PET quantifies target engagement of PD-L1 therapeutics",
abstract = "Immune checkpoint therapies have shown tremendous promise in cancer therapy. However, tools to assess their target engagement, and hence the ability to predict their efficacy, have been lacking. Here, we show that target engagement and tumor-residence kinetics of antibody therapeutics targeting programmed death ligand-1 (PD-L1) can be quantified noninvasively. In computational docking studies, we observed that PD-L1–targeted monoclonal antibodies (atezolizumab, avelumab, and durvalumab) and a high-affinity PD-L1–binding peptide, WL12, have common interaction sites on PD-L1. Using the peptide radiotracer [64Cu]WL12 in vivo, we employed positron emission tomography (PET) imaging and biodistribution studies in multiple xenograft models and demonstrated that variable PD-L1 expression and its saturation by atezolizumab, avelumab, and durvalumab can be quantified independently of biophysical properties and pharmacokinetics of antibodies. Next, we used [64Cu]WL12 to evaluate the impact of time and dose on the unoccupied fraction of tumor PD-L1 during treatment. These quantitative measures enabled, by mathematical modeling, prediction of antibody doses needed to achieve therapeutically effective occupancy (defined as >90{\%}). Thus, we show that peptide-based PET is a promising tool for optimizing dose and therapeutic regimens employing PD-L1 checkpoint antibodies, and can be used for improving therapeutic efficacy.",
author = "Dhiraj Kumar and Ala Lisok and Elyes Dahmane and Matthew McCoy and Sagar Shelake and Samit Chatterjee and Viola Allaj and Polina Sysa-Shah and Bryan Wharram and Wojciech Lesniak and Ellen Tully and Edward Gabrielson and Elizabeth Jaffee and Poirier, {John T.} and Rudin, {Charles M.} and Gobburu, {Jogarao V.S.} and Pomper, {Martin Gilbert} and Sridhar Nimmagadda",
year = "2019",
month = "2",
day = "1",
doi = "10.1172/JCI122216",
language = "English (US)",
volume = "129",
pages = "616--630",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - Peptide-based PET quantifies target engagement of PD-L1 therapeutics

AU - Kumar, Dhiraj

AU - Lisok, Ala

AU - Dahmane, Elyes

AU - McCoy, Matthew

AU - Shelake, Sagar

AU - Chatterjee, Samit

AU - Allaj, Viola

AU - Sysa-Shah, Polina

AU - Wharram, Bryan

AU - Lesniak, Wojciech

AU - Tully, Ellen

AU - Gabrielson, Edward

AU - Jaffee, Elizabeth

AU - Poirier, John T.

AU - Rudin, Charles M.

AU - Gobburu, Jogarao V.S.

AU - Pomper, Martin Gilbert

AU - Nimmagadda, Sridhar

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Immune checkpoint therapies have shown tremendous promise in cancer therapy. However, tools to assess their target engagement, and hence the ability to predict their efficacy, have been lacking. Here, we show that target engagement and tumor-residence kinetics of antibody therapeutics targeting programmed death ligand-1 (PD-L1) can be quantified noninvasively. In computational docking studies, we observed that PD-L1–targeted monoclonal antibodies (atezolizumab, avelumab, and durvalumab) and a high-affinity PD-L1–binding peptide, WL12, have common interaction sites on PD-L1. Using the peptide radiotracer [64Cu]WL12 in vivo, we employed positron emission tomography (PET) imaging and biodistribution studies in multiple xenograft models and demonstrated that variable PD-L1 expression and its saturation by atezolizumab, avelumab, and durvalumab can be quantified independently of biophysical properties and pharmacokinetics of antibodies. Next, we used [64Cu]WL12 to evaluate the impact of time and dose on the unoccupied fraction of tumor PD-L1 during treatment. These quantitative measures enabled, by mathematical modeling, prediction of antibody doses needed to achieve therapeutically effective occupancy (defined as >90%). Thus, we show that peptide-based PET is a promising tool for optimizing dose and therapeutic regimens employing PD-L1 checkpoint antibodies, and can be used for improving therapeutic efficacy.

AB - Immune checkpoint therapies have shown tremendous promise in cancer therapy. However, tools to assess their target engagement, and hence the ability to predict their efficacy, have been lacking. Here, we show that target engagement and tumor-residence kinetics of antibody therapeutics targeting programmed death ligand-1 (PD-L1) can be quantified noninvasively. In computational docking studies, we observed that PD-L1–targeted monoclonal antibodies (atezolizumab, avelumab, and durvalumab) and a high-affinity PD-L1–binding peptide, WL12, have common interaction sites on PD-L1. Using the peptide radiotracer [64Cu]WL12 in vivo, we employed positron emission tomography (PET) imaging and biodistribution studies in multiple xenograft models and demonstrated that variable PD-L1 expression and its saturation by atezolizumab, avelumab, and durvalumab can be quantified independently of biophysical properties and pharmacokinetics of antibodies. Next, we used [64Cu]WL12 to evaluate the impact of time and dose on the unoccupied fraction of tumor PD-L1 during treatment. These quantitative measures enabled, by mathematical modeling, prediction of antibody doses needed to achieve therapeutically effective occupancy (defined as >90%). Thus, we show that peptide-based PET is a promising tool for optimizing dose and therapeutic regimens employing PD-L1 checkpoint antibodies, and can be used for improving therapeutic efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85060855025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060855025&partnerID=8YFLogxK

U2 - 10.1172/JCI122216

DO - 10.1172/JCI122216

M3 - Article

C2 - 30457978

AN - SCOPUS:85060855025

VL - 129

SP - 616

EP - 630

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -